Drug Pricing Investigation: Novartis--Gleevec

Loading...
Thumbnail Image
Serial Number
Levin Center Identifier
Document Date
2020-10-01
Report Length
46 pages
Policy Agendas Project Major Code
Policy Agendas Project Minor Code
Additional, Minority, Dissenting Views
Found Using Methodology
Yes
Subcommittee(s)
Commission(s)
Idependent Author(s)
Brief Executive Summary
The House Committee on Oversight and Reform investigated Novartis International AG's actions regarding Gleevec, a drug used for treating chronic myeloid leukemia. The report, based on over 100,000 pages of internal documents, scrutinizes Novartis' pricing strategies, business practices, and efforts to minimize generic competition. The report underscores the broader issue of pharmaceutical price increases and the need for systemic reforms such as Medicare negotiation.
Press Releases and Contextual Information
Related Hearings
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Parts I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Parts II)," 116th Cong. H.Hrg. 116-123, (2020, October 1)
House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., (2021, May 18)
Authors–Congress Members
Authors–Staff Members
Authors–Ex Officio Members
Authors–Additional, Minority, Dissenting Views
Citation